The company’s stockholders will remain the registered owners of the common stock and, commencing May 13, 2009, will be able to obtain a bid and asked quotation over-the-counter.
Bioheart has remained a fully reporting company throughout this transition period and continues to make progress in its clinical projects, said Howard J. Leonhardt, chairman and chief executive officer of Bioheart.
Bioheart is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage.
Bioheart has received a written notification from Nasdaq Stock Market (Nasdaq) on February 25, 2009. Notice determines to discontinue the company’s NASDAQ listing effective as of the open of business on Friday, February 27, 2009. The company is now in the process of engaging a market maker for its common stock and causing the required application to be filed for quotation of the company’s common stock on the OTC bulletin board.
